Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...

After hours: September 18 at 7:59 PM EDT ...

China imposed a ban last year after Japan began releasing treated water from the Fukushima nuclear plant into the sea. They have agreed to expand monitoring of the water. By Daisuke Wakabayashi ...

In interviews with Fierce Pharma Marketing at Fierce’s annual Digital Pharma East event in Philadelphia last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dai-Ichi Karkaria Limited (DIK) was incorporated on 13 May 1960. The Company is engaged in manufacturing of specialty chemicals. The manufacturing activities of the Company are carried out from plants ...

BARCELONA — Mer­ck and Dai­ichi Sankyo have passed a Phase 3 with the lead an­ti­body-drug con­ju­gate from the megadeal they dis­closed at last year’s Eu­ro­pean … ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...